|
Charcot-Marie-Tooth Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We focus here on recent contributions relating vestibular and ocular motor abnormalities in inflammatory, demyelinating, metabolic, and peripheral nervous system disorders RECENT FINDINGS: Vestibular abnormalities have been identified in acute demyelinating neuropathies (AIDP), in novel genetic mutations responsible for CANVAS (cerebellar ataxia, neuropathy vestibular areflexia syndrome), and in other inherited neuropathies (variants of Charcot-Marie-Tooth disease).
|
31770124 |
2020 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The EMPA-REG, CANVAS, and DECLARE-TIMI 58 studies revealed that SGLT2 inhibitors reduce the risk of cardiovascular events and concomitantly suggested that these drugs slow the progression of kidney disease in type 2 diabetes.
|
31725011 |
2020 |
|
Muscle Rigidity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MiSet RFC Standards: Defining a Universal Minimum Set of Standards Required for Reproducibility and Rigor in Research Flow Cytometry Experiments.
|
31769204 |
2020 |
|
Rigor - Temperature-associated observation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MiSet RFC Standards: Defining a Universal Minimum Set of Standards Required for Reproducibility and Rigor in Research Flow Cytometry Experiments.
|
31769204 |
2020 |
|
Inherited neuropathies
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We focus here on recent contributions relating vestibular and ocular motor abnormalities in inflammatory, demyelinating, metabolic, and peripheral nervous system disorders RECENT FINDINGS: Vestibular abnormalities have been identified in acute demyelinating neuropathies (AIDP), in novel genetic mutations responsible for CANVAS (cerebellar ataxia, neuropathy vestibular areflexia syndrome), and in other inherited neuropathies (variants of Charcot-Marie-Tooth disease).
|
31770124 |
2020 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The three trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) (EMPA-REG OUTCOME with empagliflozin, CANVAS with canagliflozin and DECLARE with dapagliflozin) all revealed a robust and significant reduction in the hazard ratios of hospitalization for HF, from 27% to 35%, which remained consistent, significant and of similar magnitude regardless of the presence of a history of HF or established atherosclerotic cardiovascular disease.
|
30609236 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
For major cardiovascular events (MACE), there is no class effect for SGLT-2 inhibitors, as the 7% reduction of MACE risk observed with dapagliflozin in the DECLARE trial was not significant; on the other hand, a class effect is evident for both heart failure and diabetic kidney disease, as in all four trials so far completed (EMPAREG-OUTCOME, CANVAS, DECLARE, CREDENCE) the risk of hospitalization for heart failure and progression of diabetic kidney disease was significantly reduced by all SGLT-2 inhibitors.
|
31337395 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical cure rates for the modified intent-to-treat population in COVERS and CANVAS were similar for ceftaroline fosamil-treated patients with ≥1 sign of sepsis [82% (255/312) and 85% (335/394)] and for those with SIRS [84% (168/199) and 85% (131/155)].
|
30716446 |
2019 |
|
Acute leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, high mRNA levels of RFC1 are a protective factor in the risk of AL relapse (OR=0.22, 95% 0.06-0.80).
|
31452789 |
2019 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical cure rates for the modified intent-to-treat population in COVERS and CANVAS were similar for ceftaroline fosamil-treated patients with ≥1 sign of sepsis [82% (255/312) and 85% (335/394)] and for those with SIRS [84% (168/199) and 85% (131/155)].
|
30716446 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Three CVOTs of various SGLT-2i (EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58) enrolled markedly different patient populations in terms of ASCVD risk, but have demonstrated robust and consistent benefits in reduction of hospitalization for HF.
|
31081589 |
2019 |
|
Non-ST Elevated Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with NSTEMI presenting with RFC as culprit lesion at OCT evaluation have a specific perturbation of adaptive immunity, mostly involving CD4<sup>+</sup>CD28<sup>null</sup> T- cells and Tregs, as compared with patients with IFC and SA.
|
30217424 |
2019 |
|
ABSSSI
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical outcomes at test-of-cure in patients with ABSSSI and systemic inflammatory signs/systemic inflammatory response syndrome (SIRS) as well as ceftaroline minimum inhibitory concentrations (MICs) against baseline pathogens were compared between the COVERS trial (ceftaroline fosamil 600 mg q8h, 2-h infusion) and the CANVAS 1 and 2 trials (ceftaroline fosamil 600 mg q12h, 1-h infusion).
|
30716446 |
2019 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycaemia significantly decreased protein levels of RFC-1, THTR1, THTR2 and TKT (P<0.05) <i>in vitro</i>.
|
28950391 |
2018 |
|
Mycoses
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Results of blood agar plate and thin-layer chromatography analysis showed RFC-1 released high lipid and emulsification activity in the fungal culture.
|
30142606 |
2018 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Liraglutide (in LEADER), semaglutide (in SUSTAIN-6), empagliflozin (in EMPA-REG OUTCOME), and canagliflozin (in CANVAS) were all associated with reduction of the primary composite outcome (i.e. cardiovascular death, nonfatal myocardial infarction or stroke).
|
29702499 |
2018 |
|
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Liraglutide (in LEADER), semaglutide (in SUSTAIN-6), empagliflozin (in EMPA-REG OUTCOME), and canagliflozin (in CANVAS) were all associated with reduction of the primary composite outcome (i.e. cardiovascular death, nonfatal myocardial infarction or stroke).
|
29702499 |
2018 |
|
Vestibular Neuronitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The etiology includes: idiopathic: <i>n</i> = 9, Wernicke's encephalopathy <i>n</i> = 11, superficial siderosis <i>n</i> = 3, paraneoplastic syndrome: <i>n</i> = 3, bilateral vestibular neuritis (recurrent AVS lasting days without cochlear symptoms) <i>n</i> = 3, simultaneous ototoxicity of aminoglycoside and chemotherapy toxicity <i>n</i> = 2, MELAS <i>n</i> = 2, Meniere's disease treated with intra-tympanic streptomycin in one ear <i>n</i> = 1, acute phenytoin intoxication: <i>n</i> = 1, combined chronic unilateral tumor-related vestibulopathy and new contralateral vestibular neuritis (this patient presented with Betcherew's phenomenon) <i>n</i> = 1, bilateral AICA stroke <i>n</i> = 1, mixed spinocerebellar ataxia type 3, <i>n</i> = 2 and CANVAS <i>n</i> = 2.
|
29545765 |
2018 |
|
Mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma.
|
28945836 |
2017 |
|
Intracortical osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The DEGs encoding RFC may be important for the development of conventional OS, and their expression may be regulated by a number of miRNAs, including miR‑802, miR‑224‑3p and miR‑522‑3p.
|
28944822 |
2017 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ultimately, the interaction between RFC and PCNA or between CDK2 and CyclinE, the telomerase activity and the microsatellite instability (MSI) are significantly increased in the liver cancer stem cells.
|
27782152 |
2016 |
|
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The risk alleles for MRD-positivity were: A allele of VDR (OR = 2.37, 95%CI = 1.07-5.21, P = 0.03, MRD-day15); A of RFC (OR = 1.93, 95%CI = 1.05-3.52, P = 0.03, MRD-day33 and MRD-week12, P < 0.01); A of IL15 (OR = 2.30, 95%CI = 1.02-5.18, P = 0.04, MRD-day33).
|
27427275 |
2016 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ultimately, the interaction between RFC and PCNA or between CDK2 and CyclinE, the telomerase activity and the microsatellite instability (MSI) are significantly increased in the liver cancer stem cells.
|
27782152 |
2016 |
|
Pervasive Development Disorder
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A Study of Single Nucleotide Polymorphisms of the SLC19A1/RFC1 Gene in Subjects with Autism Spectrum Disorder.
|
27213354 |
2016 |
|
Autism Spectrum Disorders
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A Study of Single Nucleotide Polymorphisms of the SLC19A1/RFC1 Gene in Subjects with Autism Spectrum Disorder.
|
27213354 |
2016 |